Skip to main content

Eculizumab

Pronunciation: e-que-liz-u-mab
Generic name: eculizumab
Brand names: Soliris, Bkemv, Epysqli
Dosage form: injection for intravenous infusion
Drug class: Selective immunosuppressants

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 12, 2024.

What is eculizumab?

Eculizumab (brand names Soliris, Bkemv, Epysqli) is used to treat paroxysmal nocturnal hemoglobinuria (PNH) in adults, and a rare chronic blood disease called atypical hemolytic uremic syndrome (aHUS) in adults and children who weigh at least 11 pounds (5 kilograms).

Eculizumab is also used to treat generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AchR) antibody positive, as well as neuromyelitis optica spectrum disorder (NMOSD) in adults.

Eculizumab's mechanism of action involves binding to a specific protein called complement protein C5 in the blood, preventing it from breaking apart into other proteins that can destroy red blood cells. Eculizumab is used to treat people with genetic conditions that affect the natural defenses of their red blood cells (see How does Soliris work for PNH? for more information).

Eculizumab infusion gained FDA approval on March 16, 2007, for PNH, under the brand name Soliris. Other approvals followed. Bkemv is an interchangeable biosimilar of Soliris which can be substituted at the pharmacy level, and Epysqli is a biosimilar of Soliris that can be substituted at the prescriber level.

Ultomiris is a longer-acting monoclonal antibody also made by Alexion Pharmaceuticals that may be used to treat PNH, aHUS, gMG, and NMOSD (see How does Ultomiris compare to Soliris for PNH?).

Eculizumab REMS

Eculizumab is available only under a special program called the Ultomiris and Soliris Risk Evaluation and Mitigation Strategy (REMS), Bkemv REMS, or Epysqli REMS. Before you can receive eculizumab, your healthcare provider must:

Eculizumab side effects

The most common side effects of eculizumab are:

Serious side effects and warnings

Eculizumab carries a Boxed Warning for serious meningococcal infections.

Meningococcal infections. Eculizumab increases the risk of serious and life-threatening infections caused by meningococcal bacteria (Neisseria meningitidis). Meningococcal infections may quickly become life-threatening or cause death if not recognized and treated early.

Your healthcare provider will give you a Patient Safety Card about the risk of serious meningococcal infection. Carry it with you at all times during treatment and for 3 months after your last dose of eculizumab. Your risk of 
meningococcal infection may continue for several weeks after your last dose. It is important to show this card to any healthcare provider who treats you. This will help them diagnose and treat you quickly. 

Eculizumab may also increase the risk of other types of serious infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria gonorrhoeae.

Serious infusion-related reactions. Serious infusion-related reactions can happen during your eculizumab infusion. Tell your healthcare provider or nurse right away if you get any of these symptoms during your infusion:

If you have an infusion-related reaction to eculizumab, your healthcare provider may need to infuse it more slowly or stop eculizumab. 

Eculizumab affects your immune system. You may get infections more easily, even serious or fatal infections. Call your doctor right away if you have a headache and fever with nausea or vomiting, skin rash, body aches, flu symptoms, confusion, sensitivity to light, or stiffness in your neck or back.

Do not stop receiving eculizumab without first talking to your doctor. Stopping or interrupting your treatment could cause sudden and serious effects on your red blood cells.

Get emergency medical help if you have signs of an allergic reaction to eculizumab such as hives; chest pain, difficulty breathing; feeling like you might pass out; swelling of your face, lips, tongue, or throat. These symptoms may occur during the injection.

During or after your treatment with eculizumab call your doctor at once if you have:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Before taking this medicine

You should not use eculizumab if:

Your doctor may recommend certain vaccines. You must be vaccinated against meningococcal infection at least 2 weeks before you start treatment with eculizumab. If you were vaccinated in the past, you may need a booster dose.

Pregnancy

It is not known if eculizumab will harm an unborn baby. Follow your doctor's instructions about using this medicine if you are pregnant. It is very important to control your blood disorder during pregnancy to avoid unwanted effects in you or the baby.

Breastfeeding

Ask a doctor if it is safe to breastfeed while using eculizumab.

How is eculizumab administered?

Eculizumab is injected into a vein by a healthcare provider. The infusion can take at least 35 minutes to complete in adults or 1 to 4 hours in children.

Adults will usually receive an eculizumab infusion:

For children less than 18 years of age, your healthcare provider will decide how often you will receive eculizumab depending on your age and body weight.

After each infusion, you should be monitored for at least 1 hour for infusion-related reactions.

If you have an infusion-related reaction during your eculizumab infusion, your healthcare provider may decide to give eculizumab more slowly or stop your infusion.

If you have PNH, your healthcare provider will need to monitor you closely for at least 8 weeks after stopping eculizumab. Stopping treatment with eculizumab may cause a breakdown of your red blood cells due to PNH. Symptoms or problems that can happen due to red blood cell breakdown include:

If you have aHUS, your healthcare provider will need to monitor you closely for at least 12 weeks after stopping eculizumab for signs of worsening aHUS symptoms or problems related to abnormal clotting (thrombotic microangiopathy).

Symptoms or problems that can happen with abnormal clotting may include:

Your doctor will perform tests to make sure eculizumab is the right treatment for you.

Do not stop receiving eculizumab without first talking to your doctor. Interrupting your treatment could cause sudden and serious effects on your red blood cells.

Eculizumab dosing 

Usual Adult Eculizumab Dose for Paroxysmal Nocturnal Hemoglobinuria:

Usual Adult Eculizumab Dose for Hemolytic Uremic Syndrome:

Usual Adult Eculizumab Dose for Myasthenia Gravis:

Usual Adult Eculizumab Dose for Neuritis:

Usual Child Eculizumab Dose for Atypical Hemolytic Uremic Syndrome (aHUS):

2 months and older:
-Weight 5 kg to less than 10 kg: eculizumab 300 mg IV for the first dose, followed by 300 mg IV at week 2, then 300 mg IV every 3 weeks
-Weight 10 kg to less than 20 kg: eculizumab 600 mg IV for the first dose, followed by 300 mg IV at week 2, then 300 mg IV every 2 weeks
-Weight 20 kg to less than 30 kg: eculizumab 600 mg IV every week for the first 2 doses, followed by 600 mg IV at week 3, then 600 mg IV every 2 weeks
-Weight 30 kg to less than 40 kg: eculizumab 600 mg IV every week for the first 2 doses, followed by 900 mg IV at week 3, then 900 mg IV every 2 weeks
-Weight 40 kg or greater: eculizumab 900 mg IV every week for the first 4 doses, followed by 1200 mg IV at week 5, then 1200 mg IV every 2 weeks

What happens if I miss a dose?

Call your doctor for instructions.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while using eculizumab?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

What other drugs will affect eculizumab?

Other drugs may interact with eculizumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Does eculizumab interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

Eculizumab ingredients

Soliris

Active ingredient: eculizumab

Inactive ingredients: polysorbate 80 (vegetable origin), sodium chloride, sodium phosphate dibasic, sodium phosphate monobasic, and Water for Injection.

Bkemv

Active ingredient: eculizumab-aeeb.

Inactive ingredients: sorbitol (E420), acetic acid, polysorbate 80 (vegetable origin), edetate disodium (EDTA), sodium hydroxide may be added to adjust pH, and Water for Injection, USP.

Epysqli

Active ingredient: eculizumab-aagh.

Inactive ingredients: dibasic sodium phosphate, monobasic sodium phosphate, polysorbate 80 (vegetable origin), trehalose, and Water for Injection.

Who makes eculizumab?

Alexion Pharmaceuticals, Inc. manufactures eculizumab under the brand name Soliris.

Amgen Inc. manufactures eculizumab under the brand name Bkemv.

Samsung Bioepsis manufactures eculizumab under the brand name Epysqli.

Eculizumab Biosimilars

Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.

Reference products

These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There is 1 for eculizumab.

Soliris (eculizumab) - Alexion Pharmaceuticals, Inc.
Formulation type Strength
Single-Dose Vial 300 mg/30 mL (10 mg/mL)

View Soliris information in detail.

Soliris interchangeable products

Interchangeable biosimilar products can be dispensed by a pharmacist without the intervention of the prescriber of the reference product.

Pharmacy laws for biosimilar prescribing may vary by state.

Bkemv (eculizumab-aeeb) - Amgen Inc.
Formulation type Strength
Single-Dose Vial 300 mg/30 mL (10 mg/mL)

View Bkemv information in detail.

Soliris biosimilar products

Biosimilar products can only be dispensed in place of the reference product if the healthcare provider specifically prescribes the biosimilar product by name.

Pharmacy laws for biosimilar prescribing may vary by state

Epysqli (eculizumab-aagh) - Samsung Bioepis Co., Ltd.
Formulation type Strength
Single-Dose Vial 300 mg/30 mL (10 mg/mL)

View Epysqli information in detail.

Popular FAQ

How does Empaveli compare to Soliris?

Empaveli is a brand name for pegcetacoplan which is a PEGylated 40kDa polyethylene glycol linear small molecule that acts as a C3 complement inhibitor and Soliris is a brand name for eculizumab which is a monoclonal antibody that specifically binds to the complement protein C5. Empaveli is given by subcutaneous infusion and people can be taught how to self-administer it at home. Soliris is given by infusion under the guidance of a healthcare professional every 2 weeks (after the initial dosing schedule) although most patients are encouraged to switch from Soliris to Ultomaris which only requires 7 infusions in adults a year. Continue reading

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.